 | |
| Names | |
|---|---|
| IUPAC name N-{[(1R,2R,3S,4S)-2-Hydroxybornan-3-yl]carbamoyl}-4-methylbenzene-1-sulfonamide | |
| Systematic IUPAC name N-{[(1S,2S,3R,4R)-3-Hydroxy-4,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]carbamoyl}-4-methylbenzene-1-sulfonamide | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider |
|
| DrugBank |
|
| ECHA InfoCard | 100.043.735 |
| EC Number |
|
| KEGG |
|
| MeSH | C073323 |
| UNII | |
| |
| |
| Properties | |
| C18H26N2O4S | |
| Molar mass | 366.48 g/mol |
| Pharmacology | |
| A10BB04 (WHO) | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Glibornuride (INN) is ananti-diabetic drug from the group ofsulfonylureas.[1] It is manufactured byMEDA Pharma and sold inSwitzerland under the brand nameGlutril.[2]
Gliburnide is an endo-endo derivative made from camphor-3-carboxamide by borohydride reduction (exo approach), followed byHofmann rearrangement tocarbamate, followed by displacement with sodium tosylamide.
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
